Lehigh Valley Health Network

LVHN Scholarly Works
Department of Medicine

Isolated Gastroduodenal Crohn’s Disease
Matthew Sullivan DO
Lehigh Valley Health Network, Matthew.Sullivan@lvhn.org

Patrick Hickey DO
Lehigh Valley Health Network, Patrick.Hickey@lvhn.org

Saba Ahmad MD
Lehigh Valley Health Network, Saba.Ahmad@lvhn.org

Jeffrey Brodsky MD
Lehigh Valley Health Network, Jeffrey_T.Brodsky@lvhn.org

Hiral N. Shah MD
Lehigh Valley Health Network, hiral_n.shah@lvhn.org
See next page for additional authors

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine
Part of the Gastroenterology Commons, and the Medical Sciences Commons
Published In/Presented At
Sullivan, M.J, Hickey, P., Ahmad, S., Brodsky, J., Shah, H. & Bross, R. (2014, October, 25). Isolated Gastroduodenal Crohn’s Disease.
Poster session presented at the Pennsylvania American College of Physicians Eastern Regional Poster Competition, Harrisburg, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Authors

Matthew Sullivan DO, Patrick Hickey DO, Saba Ahmad MD, Jeffrey Brodsky MD, Hiral N. Shah MD, and
Ronald Bross MD

This poster is available at LVHN Scholarly Works: http://scholarlyworks.lvhn.org/medicine/503

Isolated Gastroduodenal Crohn’s Disease
Matthew J. Sullivan DO, Patrick Hickey DO, Saba Ahmad MD, Jeffrey Brodsky MD, Hiral Shah MD, and Ronald Bross MD
Department of Internal Medicine, Lehigh Valley Health Network, Allentown, PA

Background

Discussion

• Crohn’s disease (CD) is a chronic idiopathic inflammatory disease of the
gastrointestinal (GI) tract characterized by segmental and transmural
involvement which can occur anywhere along the GI tract.1  However, there is a
predilection for the distal small bowel and proximal colon.2 CD can also affect
extra-intestinal locations including the skin, bones, eyes, liver, gallbladder,
urinary tract, and vascular system.3  The mean age at time of presentation is 20
to 30 years.4
• The etiology and pathogenesis are not well understood, but current research
indicates that CD is likely related to an abnormal immunological response to
natural intestinal flora in genetically-susceptible patients.  Genetic, epigenetic,
and environmental factors are thought to also play a role and cigarette smoking
2
has been identified as an independent risk factor.   
• Active CD is characterized by focal inflammation and fistula formation resulting
in fibrosis, stricturing, and thickening of the bowel wall which can lead to
recurrent obstructions or chronic fistulas.  Presenting symptoms depend on the
portion of the GI tract which is affected, but include abdominal pain, diarrhea,
nausea, vomiting, and weight loss.3  Gastroduodenal involvement in CD is
typically asymptomatic, but when symptoms do occur the most common is
epigastric pain, often postprandial, which can lead to weight loss and anorexia.4
• The pathologic hallmark of CD is a granulomatous inflammatory response
characterized by focal collections of macrophages, epithelioid cells, and
2
multinucleated giant cells.   However, a focal nonspecific acute and chronic
5
inflammation is more common in upper GI tract involvement.   The most
common pathology finding in gastric CD is a Helicobacter pylori-negative focal
4
gastritis.   
• Approximately one-third of patients have ileitis or colitis at the time of diagnosis2,
but only 0.5-4% of all patients with CD have clinically significant gastroduodenal
disease.4 The majority of these patients have concomitant distal disease and
there are only a few documented case reports of adults with isolated gastric CD,
accounting for only 0.07% of all cases of CD.1  The first case of gastric CD was
described in 1949.5
• Imaging in gastroduodenal CD can show aphthous ulcers, “cobblestoning,”
thickened folds, ulcerations, “ram’s horn sign,” and a “pseudo-Billroth I
appearance” of the antrum and proximal duodenum.  Endoscopy with biopsy
4
remains the gold standard for diagnosis.
• Initial treatment of gastroduodenal CD includes corticosteroids and acid
suppression with proton pump inhibitor.  After remission, 6-mercaptopurine and
azathioprine are used for maintenance treatment.  One third of patients will
require surgery due to duodenal obstruction, refractory pain, fistula formation, or
hemorrhage.4

This case demonstrates a rare presentation of isolated gastroduodenal Crohn’s disease (CD) and the
difficulty in making this diagnosis.  Nugent and Roy developed criteria for diagnosing gastroduodenal CD
which include:
• Noncaseating granulomatous inflammation of the stomach or duodenum and the absence of other
systemic granulomatous disorders, or
• Confirmed CD elsewhere and radiographic or endoscopic evidence of CD involvement of the stomach or
duodenum.4
Significant gastroduodenal involvement occurs in only 0.5-4% of all CD patients and even less have isolated
4
disease. However, due to advancement of diagnostics, non-significant incidence is thought to be much
5
more prevalent.
Examination for lower gastrointestinal tract involvement and malignancy must be ruled out prior to making
the diagnosis.  Close follow up is also imperative as one-third of patients with gastroduodenal CD will
develop distal disease over time.4
The symptoms of gastroduodenal CD can easily be confused with peptic ulcer disease (PUD) and this
4
must also be ruled out. Helicobacter pylori testing should be completed as the most common finding is a
5
nonspecific acute and chronic inflammation which is most often H. pylori-negative. Also, ulcerations in CD
are typically linear as opposed to the circular ulcers seen with PUD.
Initially our patient did not meet the Nugent and Roy criteria.  Under these circumstances antiSaccharomyces cervisia antibody testing may be beneficial and this was indeed positive in our patient.3
Despite repeated imaging and endoscopies, our patient did not receive a diagnosis until after surgical
resection, demonstrating the complexity in making the diagnosis of isolated gastroduodenal Crohn’s
disease.

Case Presentation
A 69-year-old female former smoker without any known past medical or
family history of gastrointestinal disease and malignancy presented with
intermittent dysphagia to both solids and liquids associated with severe
chest pain.
Initial workup included esophagogastroduodenoscopy (EGD) revealing a
small sliding hiatal hernia, mild non-erosive gastritis with benign appearing
gastric polyps, and an irregular Z-line which was biopsied to rule out
short segment Barrett’s esophagus.  The duodenum was unremarkable.  A
colonoscopy was also performed revealing only diverticulosis.  She was
initiated on proton pump inhibitor (PPI) therapy due to the finding of gastritis.
Two years later she presented with complaints of nausea, epigastric pain,
and early satiety over the previous three weeks.  A CT scan of the abdomen
was performed revealing gastric antral wall thickening and inflammatory
stranding.
EGD demonstrated erosions and submucosal hemorrhages in the gastric
antrum and pyloric channel.  There was also severe bulbar duodenitis with
exudate and friability.  Multiple biopsies were obtained revealing chronic
active inflammation and the patient was maintained on PPI therapy.
Her early satiety progressed and continued weight loss lead to a third EGD
with endoscopic ultrasound (EUS).  This revealed marked erythematous
mucosa with an irregular pattern throughout the antrum with areas of pitting
and hypertrophy in a “stalactite” fashion.  There was also narrowing of the
antrum without gastric outlet obstruction.  The echoendoscope revealed 2
cm circumferential thickening of the antrum with loss of native architecture.  
Using fine needle aspiration, multiple biopsies were obtained of the gastric
antrum.  There was no evidence of perigastric lymphadenopathy or liver
pathology visualized.  Biopsies again revealed chronic active inflammation
and cytology was negative for malignancy.
At this point the patient was referred to an oncologic surgeon due
to concern for possible gastric malignancy.  The patient eventually
underwent partial distal gastrectomy with Roux-en-Y reconstruction.  The
surgical specimen was sent for pathology which revealed multiple foci of
inflammation with submucosal fibrosis and deep non-caseating granulomas
consistent with Crohn’s disease.

Figure 1. Endoscopic ultrasound revealing
circumferential thickening of the gastric wall.

Figure 2. EGD image demonstrating gastritis
and erythema of the antrum and marked
hypertrophy of the mucosa with narrowing of
the pyloric channel.
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Figure 3. EGD image of the pyloric channel
again demonstrating mucosal irregularities and
areas of hypertrophy and pitting.
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Figure 4. Slide preparation from gastric
antrum showing focally necrotizing granulomatous
inflammation consistent with Crohn’s Disease.

